Abstract: Objectives: To investigate if preoperative neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), or mean platelet volume (MPV) could be used to predict 1-year mortality in patients undergoing open abdominal aortic aneurysm (AAA) repair. Methods: We retrospectively reviewed 382 patients who underwent open AAA repair between January 2008 and July 2019. We divided the patients into two groups based on 1-year mortality and compared the preoperative NLR, PLR, and MPV. The patients were then classified into tertiles based on their preoperative NLR, and compared across the aforementioned tertiles. An additional subgroup analysis was performed by dividing the cases into non-ruptured and ruptured cases. Results: The preoperative NLR was significantly higher in the non-survivor group than in the survivor group (10.53 ± 9.60 vs. 5.76 ± 6.44, respectively, p = 0.003). The PLR and MPV were similar between the groups (145.35 ± 91.11 vs. 154.20 ± 113.19, p = 0.626, 9.38 ± 1.20 vs. 9.11 ± 1.39, p = 0.267, respectively). The incidence of 1-year mortality was 2.7%, 9.0%, and 14.3% in the first, second, and third NLR tertiles, respectively (p = 0.009). Higher NLR (odds ratio 1.085, 95% confidence interval 1.016–1.159, p = 0.015) and ruptured AAA (odds ratio 2.706, 95% confidence interval 1.097–6.673, p = 0.031) were the independent predictors of 1-year mortality in all patients. Moreover, the preoperative NLR was significantly higher in the ruptured AAA than in the non-ruptured AAA group (11.17 ± 7.90 vs. 4.10 ± 4.75, p < 0.001). In subgroup analysis, preoperative NLR (odds ratio 1.144, 95% confidence interval 1.031–1.271, p = 0.012) and PLR (odds ratio 0.986, 95% confidence interval 1.097–0.998, p = 0.017) was an independent predictor for 1-year mortality in ruptured cases. Conclusions: We demonstrated an independent relationship between the preoperative NLR and 1-year mortality in patients undergoing open AAA repair, besides PLR and MPV. Furthermore, the NLR and PLR had predictive power for 1-year mortality in ruptured cases.

Keywords: neutrophil to lymphocyte ratio; platelet to lymphocyte ratio; mean platelet volume; aortic surgery; abdominal aortic aneurysm

1. Introduction

Abdominal aortic aneurysm (AAA) is a multifactorial degenerative disorder, which if untreated can lead to catastrophic complications [1]. The treatment for AAA includes open and endovascular repair, both of which carry a significant degree of risk [2,3]. Furthermore, AAA accompanies several serious comorbidities such as advanced age, hypertension,
diabetes mellitus (DM), hyperlipidemia and smoking, which can worsen prognosis [3,4]. Thus, researchers have performed several studies addressing simple and readily available risk stratification markers, such as complete blood count in patients undergoing open AAA repair [5–7].

The neutrophil to lymphocyte ratio (NLR) has been frequently used as a marker of the systemic inflammatory response, which reflects neutrophilia and lymphopenia [8]. The primary pathophysiology of AAA involves chronic inflammation in the aortic wall and atherosclerosis, accompanied by thrombosis [9]. NLR was proposed as a fair indicator of poor prognosis in patients with AAA [6,10,11]. The mean platelet volume (MPV) is a marker of platelet activation and an indicator of the activation of thrombus formation. Moreover, it is reportedly associated with the prognosis of patients with cardiovascular diseases [12]. Moreover, the platelet to lymphocyte ratio (PLR) suggests thrombosis and inflammation and indicates a high risk of cardiovascular events in various groups of patients [13]. The PLR is associated with poor prognosis following AAA repair [5]. NLR, PLR and MPV have also been investigated in other, non-vascular diseases such as obesity, DM, and nonalcoholic fatty liver disease (NAFLD). Platelet indices have also been reported to have a predictive role for fibrosis [14]. Despite accumulating evidence for the prognostic value of white blood cell counts in abdominal aortic aneurysms [6,10,15], few studies have investigated the value of these parameters, including NLR, MPV and PLR in patients undergoing AAA open repair.

We aimed to assess the NLR, MPV and PLR as valuable predictors of perioperative mortality in patients undergoing open repair for AAA.

2. Materials & Methods
2.1. Study Population

Following approval by the institutional review board of the Yonsei University Health System, Seoul, South Korea (IRB protocol No. 3-2020-0479), the requirement for informed consent was waived considering the retrospective nature of this study. The study comprised 382 patients who underwent an AAA open repair at the Gangnam Severance hospital between January 2008 and July 2019. Patients with previous aortic repair within 6 months (n = 8), mycotic aneurysm (n = 5), iliac artery aneurysm (n = 10), aorta occlusive disease (n = 1), hematologic malignancy (n = 0), liver cirrhosis (n = 0), or incomplete laboratory data (n = 24) were excluded from the analysis. We eventually analyzed 334 patients (Figure 1). We divided the patients into survivors and non-survivors, and analyzed three classified groups based on their preoperative NLR levels (first tertile: NLR < 2.41 (n = 111); second tertile: 2.41 ≤ NLR ≤ 6.07 (n = 111); and third tertile: NLR > 6.07 (n = 112)).

2.2. Demographic and Clinical Data

Patient demographic and clinical data included their sex, age, body mass index (BMI), comorbidities (hypertension, diabetes mellitus, cerebrovascular accident (CVA), coronary artery occlusive disease, chronic obstructive pulmonary disease, and chronic kidney disease), and smoking. Preoperative steroid use was recorded. Perioperative laboratory data comprised the complete blood count, NLR, MPV, PLR, prothrombin time (PT), C-reactive protein (CRP), B-type natriuretic peptide, creatinine, blood urea nitrogen (BUN), and estimated glomerular filtration rate (eGFR). We recorded the etiology of the disease, intake and output during surgery, and the total duration of surgery. The incidence of postoperative complications, including intensive care unit (ICU) readmission, reoperation, the requirement of renal replacement therapy, pulmonary complications, infection, acute kidney injury, myocardial infarction, cerebrovascular accidents, and mortality was collected. Moreover, we recorded the duration of hospitalization and ICU stay.
2.3. Study Endpoints

The incidence of 1-year mortality after AAA open repair was the primary endpoint. By contrast, the secondary outcome comprised the incidence of postoperative complications including infections, pulmonary complication, myocardial infarction, CVA, and acute kidney injury within 48 h following the surgery. Myocardial infarction was defined as an increase in the peak serum troponin-T isozyme >5 times the upper limit of normal. CVA was defined as the presence of recent neurological deterioration induced by embolic, thrombotic, or hemorrhagic brain injury. Infection was defined as the occurrence of one of the following conditions: pneumonia, sepsis, peritonitis, urinary tract infection, or graft infection. Pulmonary complication was defined as respiratory failure, an exacerbation of chronic obstructive pulmonary disease, or culture-negative pneumonia that required prolonged mechanical ventilation (>24 h). Acute kidney injury within 48 h following surgery was defined using the Kidney Disease Improving Global Guidelines Clinical Practice Guidelines.

2.4. Statistical Analyses

SPSS version 23 (IBM Corp, Armonk, NY, USA) was used to perform all statistical analyses. All results are described as means ± standard deviations or the number of patients (%). We assessed the normality using the Kolmogorov-Smirnov test. We conducted independent t-tests or Mann-Whitney U tests to compare continuous variables. While one-way analysis of variance or Kruskal-Wallis tests were used to compare the three groups, Bonferroni’s method was used for post-analysis. We compared the categorical variables using the chi-square test or Fisher’s exact test. Moreover, we performed a logistic regression analysis to evaluate the predictors for 1-year mortality. For the multivariate analysis, we performed a stepwise selection method, and selected variables with $p < 0.2$ in the univariate analysis. Predictability was expressed as the odds ratio (OR) and 95% confidence interval (CI). A $p$-value < 0.05 was considered statistically significant.
3. Results
3.1. Baseline and Perioperative Characteristics

A total of 382 patients were reviewed during the study period, and 334 patients were eventually analyzed (Figure 1). Table 1 summarizes the baseline characteristics of patients, compared to their 1-year mortality. Baseline characteristics, including their sex, age, BMI, and medical history, were similar between the groups. Ruptured AAA was more frequent in the non-survivor group (26.6% vs. 58.6%, respectively, \( p < 0.001 \)) as well as in emergency cases (54.8% vs. 89.7%, respectively, \( p < 0.001 \)). The preoperative white blood cell count and neutrophil count were higher in the non-survivor group than in the survivor group (9661.15 ± 4531.01/µL vs. 14328.62 ± 6821.57/µL, respectively, \( p = 0.001 \) and 7089.71 ± 4543.53/µL vs. 11833.71 ± 6670.75/µL, respectively, \( p < 0.001 \)). In contrast, the preoperative lymphocyte count was lower in the non-survivor group than in the survivor group (1712.39 ± 814.84/µL vs. 1483.16 ± 689.47/µL, respectively, \( p < 0.001 \)). The non-survivor group revealed lower preoperative hemoglobin levels than the survivor group (12.07 ± 2.61 g/dL vs. 10.39 ± 2.66 g/dL, respectively, \( p = 0.001 \)). Moreover, the preoperative hematocrit was lower in the non-survivor group than in the survivor group (36.25 ± 7.54% vs. 31.39 ± 7.81%, respectively, \( p = 0.001 \)). However, the platelet count was not significantly different between the groups (204,328.31 ± 72,993.61/µL vs. 187,206.90 ± 107,334.38/µL, \( p = 0.407 \)). The preoperative NLR was significantly higher in the non-survivor group than in the survivor group (5.76 ± 6.44 vs. 10.53 ± 7.60, respectively, \( p = 0.003 \)). The MPV and PLR values demonstrated inconsequential differences between the two groups (9.38 ± 1.20 fL vs. 9.11 ± 1.39 fL, respectively, \( p = 0.267 \), 145.35 ± 91.11 vs. 154.20 ± 113.19, respectively, \( p = 0.626 \)). The non-survivor group had more prolonged PT (INR) and higher preoperative BUN levels than the survivor group (1.11 ± 0.24 vs. 1.47 ± 0.54, respectively, \( p = 0.002 \) and 20.06 ± 9.69 mg/dL vs. 24.32 ± 10.80 mg/dL, respectively, \( p = 0.028 \)), along with lower eGFR values (59.00 ± 24.87 mL/min/1.73 m² vs. 72.89 ± 22.87 mL/min/1.73 m², respectively, \( p = 0.024 \)). However, creatinine levels did significantly differ between the groups (1.17 ± 0.82 mg/dL vs. 1.32 ± 0.49 mg/dL, respectively, \( p = 0.323 \)).

Table 2 outlines the baseline characteristics and operation-related data based on preoperative NLR levels across the first, second, and third tertiles. Baseline characteristics were similar among the three groups, except for age (69.08 ± 8.82 vs. 73.07 ± 9.55 vs. 73.30 ± 9.12, respectively, \( p = 0.001 \)) and history of hypertension (76.4% vs. 61.3% vs. 70.5%, respectively, \( p = 0.049 \)). The proportion of ruptured AAA (3.6% vs. 21.6% vs. 62.5%, respectively, \( p < 0.001 \)) and emergency surgery (25.2% vs. 52.3% vs. 95.5%, respectively, \( p < 0.001 \)) was significantly different among the tertiles. The third tertile group received more packed red blood cells and fresh frozen plasma transfusions than any other group (21.72 ± 3.10 packs, \( p < 0.001 \), 0.77 ± 0.49 mg/dL, \( p < 0.001 \)). The reintubation rate was the highest in the third tertile group. (6.3% vs. 10.8% vs. 30.4%, respectively, \( p < 0.001 \)). Re-operation because of postoperative bleeding was most frequent in the third tertile group (0.9% vs. 1.8% vs. 7.1%, respectively, \( p = 0.046 \)). Patients in the highest NLR tertile reported more pulmonary complications and postoperative infections (7.2% vs. 19.8% vs. 24.1%, \( p = 0.002 \), 3.6% vs. 7.2% vs. 15.2%, \( p = 0.007 \)), respectively. Moreover, the third tertile group comprised the highest in-hospital mortality of any group (2.7% vs. 9.0% vs. 13.4%, respectively, \( p = 0.015 \)). We observed similar results for 1-month mortality and 1-year mortality (1.8% vs. 6.3% vs. 10.7%, \( p = 0.023 \), 2.7% vs. 9.0% vs. 14.3% \( p = 0.009 \), respectively).
**Table 1.** Baseline characteristics and laboratory data, stratified according to 1-year mortality.

|                        | Survivor (n = 305) | Non-Survivor (n = 29) | p-Value |
|------------------------|--------------------|-----------------------|---------|
| Female sex             | 61 (20.0%)         | 2 (6.9%)              | 0.085   |
| Age (years)            | 71.69 ± 9.42       | 73.28 ± 8.54          | 0.382   |
| Height (cm)            | 165.35 ± 8.25      | 166.04 ± 8.11         | 0.389   |
| Weight (kg)            | 64.51 ± 11.19      | 64.56 ± 13.30         | 0.985   |
| BMI                    | 23.51 ± 3.13       | 23.42 ± 4.52          | 0.925   |
| Smoking                | 113 (37.0%)        | 11 (37.9%)            | 0.925   |
| HTN                    | 214 (70.4%)        | 17 (58.6%)            | 0.189   |
| DM                     | 54 (17.7%)         | 5 (17.2%)             | 0.950   |
| CVA                    | 43 (14.1%)         | 5 (17.2%)             | 0.586   |
| CAOD                   | 72 (23.7%)         | 8 (27.6%)             | 0.638   |
| COPD                   | 7 (2.3%)           | 1 (3.4%)              | 0.520   |
| CRF                    | 26 (8.5%)          | 1 (3.4%)              | 0.491   |
| ESRD                   | 3 (1.0%)           | 0                     | 1.000   |
| Rupture                | 81 (26.6%)         | 17 (58.6%)            | <0.001 *|
| Emergency              | 167 (54.8%)        | 26 (89.7%)            | <0.001 *|
| Preop steriod          | 5 (1.6%)           | 0                     | 1.000   |
| Preop WBC (/µL)        | 9661.15 ± 4531.01  | 14,328.62 ± 6821.57   | 0.001 * |
| Preop neutrophil (/µL) | 7089.71 ± 4543.53  | 11,833.71 ± 6670.75   | <0.001 *|
| Preop lymphocyte (/µL) | 1712.39 ± 814.84   | 1483.16 ± 689.47      | <0.001 *|
| Preop Hb (g/dL)        | 12.07 ± 2.61       | 10.39 ± 2.66          | 0.001 * |
| Preop Hct (%)          | 36.25 ± 7.54       | 31.39 ± 7.81          | 0.001 * |
| Preop PLT (/µL)        | 204,328.31 ± 72993.61 | 187,206.90 ± 107334.38 | 0.407   |
| Preop NLR              | 5.76 ± 6.44        | 10.53 ± 7.60          | 0.003 * |
| Preop MPV (fL)         | 9.38 ± 1.20        | 9.11 ± 1.39           | 0.267   |
| Preop PLR              | 145.35 ± 91.11     | 154.20 ± 113.19       | 0.626   |
| Preop PT (INR)         | 1.11 ± 0.24        | 1.47 ± 0.54           | 0.002 * |
| Preop procalcitonin (ng/mL) | 0.22 ± 0.73   | 0.45 ± 0.41          | 0.402   |
| Preop CRP (mg/L)       | 21.87 ± 43.82      | 35.84 ± 47.59         | 0.234   |
| Preop BNP (pg/mL)      | 166.52 ± 300.09    | 234.42 ± 264.01       | 0.488   |
| Preop BUN (mg/dL)      | 20.06 ± 9.69       | 24.32 ± 10.80         | 0.028 * |
| Preop Cr (mg/dL)       | 1.17 ± 0.82        | 1.32 ± 0.49           | 0.323   |
| Preop eGFR (mL/min/1.73 m²) | 72.89 ± 22.87   | 59.00 ± 24.87         | 0.024 * |

Values are presented as means ± standard deviations or number of patients (%). BMI: body mass index, HTN: hypertension, DM: diabetes mellitus, CVA: cerebrovascular accident, CAOD: coronary artery occlusive disease, COPD: chronic obstructive pulmonary disease, CRF: chronic renal failure, ESRD: end stage renal disease, Hb: hemoglobin, Hct: hematocrit, PLT: platelet, NLR: neutrophil to lymphocyte ratio, MPV: mean platelet volume, PLR: platelet to lymphocyte ratio, PT: prothrombin time, CRP: C-reactive protein, BNP: B type natriuretic peptide, BUN: blood urea nitrogen, Cr: creatinine, eGFR: estimated glomerular filtration rate * p < 0.05.
Table 2. Baseline characteristics and operation related data across three NLR tertiles.

|                      | First Tertile (n = 111) | Second Tertile (n = 111) | Third Tertile (n = 112) | p-Value |
|----------------------|-------------------------|--------------------------|-------------------------|---------|
| Female sex           | 23 (20.7%)              | 19 (17.1%)               | 21 (18.8%)              | 0.790   |
| Age (years)          | 69.08 ± 8.82            | 73.07 ± 9.55             | 73.30 ± 9.12            | 0.001 * |
| Height (cm)          | 164.85 ± 9.22           | 164.99 ± 7.78            | 166.38 ± 7.56           | 0.321   |
| Weight (kg)          | 65.85 ± 12.04           | 63.72 ± 11.42            | 63.94 ± 10.48           | 0.309   |
| BMI                  | 24.12 ± 3.32            | 23.37 ± 3.28             | 22.99 ± 3.05            | 0.032   |
| Smoking              | 42 (37.8%)              | 41 (36.9%)               | 41 (36.6%)              | 0.981   |
| HTN                  | 84 (76.4%)              | 68 (61.3%)               | 79 (70.5%)              | 0.049 * |
| DM                   | 23 (20.7%)              | 16 (14.4%)               | 20 (17.9%)              | 0.467   |
| CVA                  | 18 (16.2%)              | 13 (11.7%)               | 17 (15.2%)              | 0.605   |
| CAOD                 | 27 (24.3%)              | 32 (29.1%)               | 21 (18.8%)              | 0.196   |
| COPD                 | 1 (0.9%)                | 5 (4.5%)                 | 2 (1.8%)                | 0.236   |
| CRF                  | 8 (7.2%)                | 8 (7.2%)                 | 11 (9.8%)               | 0.710   |
| ESRD                 | 0                       | 1 (0.9%)                 | 2 (1.8%)                | 0.776   |
| Rupture              | 4 (3.6%)                | 24 (21.6%)               | 70 (62.5%)              | <0.001 *|
| Emergency            | 28 (25.2%)              | 58 (52.3%)               | 107 (95.5%)             | <0.001 *|
| Preop steroid        | 1 (0.9%)                | 3 (2.7%)                 | 1 (0.9%)                | 0.542   |
| Amount of crystalloid (mL) | 2875.94 ± 1796.88    | 2675.95 ± 1675.66        | 3182.89 ± 1592.65       | 0.089   |
| Amount of colloid (mL) | 442.59 ± 591.56        | 503.18 ± 615.34          | 554.09 ± 772.70         | 0.465   |
| Urine output (mL)    | 443.70 ± 364.54         | 427.06 ± 362.91          | 458.11 ± 458.75         | 0.851   |
| Cell saver (mL)      | 443.70 ± 364.54         | 427.06 ± 362.91          | 458.11 ± 458.75         | 0.505   |
| Bleeding (mL)        | 974.84 ± 881.08         | 1121.82 ± 1345.87        | 1356.09 ± 1679.08       | 0.156   |
| pRBC transfusion (pack) | 1.07 ± 2.01             | 1.50 ± 2.54              | 3.34 ± 4.26             | <0.001 *|
| FFP (pack)           | 0.77 ± 1.71             | 1.02 ± 2.06              | 2.27 ± 3.10             | <0.001 *|
| PLTconc (pack)       | 0.76 ± 2.68             | 0.77 ± 2.87              | 1.96 ± 4.99             | 0.062   |
| Operative time (min) | 140.22 ± 74.89          | 135.56 ± 56.73           | 148.06 ± 65.23          | 0.361   |
| Anesthesia time (min) | 218.77 ± 84.55           | 203.53 ± 62.35           | 198.84 ± 71.67          | 0.108   |
| ACC time (min)       | 42.03 ± 19.80           | 36.27 ± 17.21            | 42.59 ± 22.08           | 0.066   |

Values are presented as mean ± standard deviation or number of patients (%). BMI: body mass index, HTN: hypertension, DM: diabetes mellitus, CVA: cerebrovascular accident, CAOD: coronary artery occlusive disease, COPD: chronic obstructive pulmonary disease, CRF: chronic renal failure, ESRD: end stage renal disease, pRBC: packed RBC, FFP: fresh frozen plasma, PLTconc: platelet concentrate, ACC: aorta cross clamp * p < 0.05.

3.2. Independent Prognostic Significance of NLR, MPV, and PLR in Predicting 1-Year Mortality after AAA Open Repair

Table 4 summarizes the logistic regression analysis for the predictors of 1-year mortality after AAA open repair. In the univariate analysis, ruptured AAA, preoperative NLR, PLR, and MPV revealed a difference of p < 0.2 and were selected for the multivariate analysis. Ruptured AAA (OR 2.706, 95% CI 1.097–6.673, p = 0.031) and preoperative NLR (OR 1.085, 95% CI 1.016–1.159, p = 0.015) remained the independent predictors for 1-year mortality after AAA open repair. To verify the prognostic impact of NLR, an additional subgroup analysis was performed by dividing the cases into non-ruptured and ruptured cases. Preoperative NLR (OR 1.144, 95% CI 1.031–1.271, p = 0.012) and PLR (OR 0.986, 95% CI 0.975–0.998, p = 0.017) were independent predictors for 1-year mortality in ruptured cases.
Table 3. Postoperative morbidity and mortality across three NLR tertiles.

|                | First Tertile (n = 111) | Second Tertile (n = 111) | Third Tertile (n = 112) | p-Value |
|----------------|-------------------------|--------------------------|-------------------------|---------|
| HOD (days)     | 14.02 ± 13.97           | 20.29 ± 21.72            | 19.65 ± 15.31           | 0.005 * |
| ICU (days)     | 6.04 ± 61.20            | 3.49 ± 5.64              | 6.43 ± 9.25             | 0.805   |
| Reintubation   | 7 (6.4%)                | 11 (10.3%)               | 22 (20.0%)              | 0.007 * |
| MV > 24 h      | 7 (6.3%)                | 12 (10.8%)               | 34 (30.4%)              | <0.001 *|
| ICU readmission| 7 (6.3%)                | 13 (11.7%)               | 9 (8.0%)                | 0.344   |
| Reopen for bleeding | 1 (0.9%)       | 2 (1.8%)                | 8 (7.1%)                | 0.046 * |
| CVA            | 2 (1.8%)                | 1 (0.9%)                 | 2 (1.8%)                | 1.000   |
| New RRT        | 2 (1.8%)                | 6 (5.4%)                 | 4 (3.6%)                | 0.358   |
| Pulmonary Cx   | 8 (7.2%)                | 22 (19.8%)               | 27 (24.1%)              | 0.002 * |
| Infection      | 4 (3.6%)                | 8 (7.2%)                 | 17 (15.2%)              | 0.007 * |
| Wound infection| 0                       | 1 (0.9%)                 | 2 (1.8%)                | 0.776   |
| AKI            | 50 (45.0%)              | 45 (40.9%)               | 55 (50.0%)              | 0.399   |
| MI             | 1 (0.9%)                | 3 (2.7%)                 | 3 (2.7%)                | 0.707   |
| In-hospital mortality | 3 (2.7%)     | 10 (9.0%)               | 15 (13.4%)              | 0.015 * |
| 1-month mortality | 2 (1.8%)           | 7 (6.3%)                | 12 (10.7%)              | 0.023 * |
| 1-year mortality | 3 (2.7%)            | 10 (9.0%)               | 16 (14.3%)              | 0.009 * |

Values are presented as means ± standard deviations or number of patients (%). HOD: hospital day, ICU: intensive care unit, MV: mechanical ventilation, CVA: cerebrovascular accident, RRT: renal replacement therapy, Pulmonary Cx: pulmonary complication, AKI: acute kidney injury, MI: myocardial infarction * p < 0.05.

3.3. Baseline and Perioperative Characteristics Depending on the Presence of Rupture

Table 5 outlines the baseline laboratory data stratified according to the presence of rupture in patients with AAA. In ruptured AAA cases, the preoperative white blood cell count and neutrophil count were higher than those in non-ruptured cases. (14,442.14 ± 5960.32/µL vs. 8249.36 ± 2931.44/µL, p < 0.001, 12,154.97 ± 5628.89/µL vs. 5569.29 ± 2947.05/µL, p < 0.001, respectively). By contrast, the lymphocyte count was significantly lower in the ruptured cases (1374.01 ± 670.37/µL vs. 1824.74 ± 822.26/µL, respectively, p < 0.001). While the preoperative NLR and MPV was higher in ruptured AAA than in non-ruptured AAA cases (11.17 ± 7.90 vs. 4.10 ± 4.75, p < 0.001, 9.59 ± 1.24 vs. 9.26 ± 1.19, p = 0.023, respectively), the PLR did not significantly differ between the groups (142.22 ± 84.14 vs. 155.52 ± 111.62, respectively, p = 0.291). The hemoglobin, hematocrit, and platelet levels were significantly lower in patients with ruptured AAA (12.85 ± 2.13 g/dL vs. 9.70 ± 2.47 g/dL, p < 0.001, 38.47 ± 6.13% vs. 29.47 ± 7.30%, p < 0.001, 217,017.52 ± 71,052.99/µL vs. 168,704.08 ± 78,781.86/µL, p < 0.001, respectively). Moreover, they demonstrated prolonged PT (INR) and higher preoperative lactate levels than those with non-ruptured AAA (1.06 ± 0.16 mmol/L vs. 1.35 ± 0.42 mmol/L, p < 0.001 and 0.97 ± 0.41 vs. 4.45 ± 2.66, p < 0.001, respectively).
Table 4. Logistic regression analysis for the predictors of 1-year mortality after AAA open repair.

|                      | Univariate OR (CI)     | p-Value | Multivariate OR (CI)          | p-Value |
|----------------------|------------------------|---------|-------------------------------|---------|
| **All Patients**     |                        |         |                               |         |
| Age                  | 1.027 (0.979–1.076)    | 0.277   |                               |         |
| Rupture              | 2.859 (1.131–7.225)    | 0.026   | 2.706 (1.097–6.673)           | 0.031 * |
| Smoking              | 1.255 (0.524–3.005)    | 0.610   |                               |         |
| HTN                  | 0.619 (0.258–1.483)    | 0.282   |                               |         |
| DM                   | 1.096 (0.369–3.258)    | 0.869   |                               |         |
| CAOD                 | 1.483 (0.590–3.724)    | 0.402   |                               |         |
| CVA                  | 1.356 (0.436–4.214)    | 0.599   |                               |         |
| CKD                  | 0.430 (0.050–3.663)    | 0.440   |                               |         |
| NLR                  | 1.077 (1.007–1.152)    | 0.030   | 1.085 (1.016–1.159)           | 0.015 * |
| PLR                  | 0.996 (0.990–1.002)    | 0.181   | 0.995 (0.989–1.001)           | 0.103   |
| MPV                  | 0.710 (0.496–1.016)    | 0.061   | 0.716 (0.504–1.019)           | 0.063   |
| **Non-rupture**      |                        |         |                               |         |
| Age                  | 1.010 (0.941–1.085)    | 0.782   |                               |         |
| Smoking              | 0.886 (0.229–3.428)    | 0.860   |                               |         |
| HTN                  | 0.408 (0.113–1.465)    | 0.169   | 0.403 (0.125–1.295)           | 0.127   |
| DM                   | 0.623 (0.071–5.440)    | 0.668   |                               |         |
| CAOD                 | 1.252 (0.310–5.052)    | 0.752   |                               |         |
| CVA                  | 1.875 (0.360–9.756)    | 0.455   |                               |         |
| CKD                  | 1.863 (0.201–17.258)   | 0.584   |                               |         |
| NLR                  | 1.040 (0.954–1.133)    | 0.376   |                               |         |
| PLR                  | 1.003 (0.996–1.009)    | 0.440   |                               |         |
| MPV                  | 0.773 (0.440–1.357)    | 0.730   |                               |         |
| **Rupture**          |                        |         |                               |         |
| Age                  | 1.025 (0.955–1.101)    | 0.495   |                               |         |
| Smoking              | 0.852 (0.528–6.494)    | 0.336   |                               |         |
| HTN                  | 0.888 (0.244–3.225)    | 0.857   |                               |         |
| DM                   | 1.568 (0.368–6.676)    | 0.543   |                               |         |
| CAOD                 | 1.791 (0.474–6.767)    | 0.390   |                               |         |
| CVA                  | 0.890 (0.162–4.887)    | 0.893   |                               |         |
| CKD                  | 0.000 (0.000)          | 0.999   |                               |         |
| NLR                  | 1.139 (1.020–1.271)    | 0.020   | 1.144 (1.031–1.271)           | 0.012 * |
| PLR                  | 0.988 (0.977–1.000)    | 0.047   | 0.986 (0.975–0.998)           | 0.017 * |
| MPV                  | 0.617 (0.367–1.037)    | 0.069   | 0.616 (0.374–1.013)           | 0.056   |

Values are presented as odds ratios (95% confidence intervals). HTN: hypertension, DM: diabetes mellitus, CAOD: coronary artery occlusive disease, CVA: cerebrovascular accident, CKD: chronic kidney disease, NLR: neutrophil to lymphocyte ratio, PLR: platelet to lymphocyte ratio, MPV: mean platelet volume * p < 0.05.
Table 5. Laboratory data according to the presence of rupture.

|                      | Non-Rupture (n = 236) | Rupture (n = 98) | p-Value  |
|----------------------|------------------------|------------------|----------|
| Preop WBC (/µL)     | 8249.36 ± 2931.44      | 14,442.14 ± 5960.32 | <0.001 * |
| Preop neutrophil (/µL) | 5569.29 ± 2947.05      | 12,154.97 ± 5628.89 | <0.001 * |
| Preop lymphocyte (/µL) | 1824.74 ± 822.26      | 1374.01 ± 670.37  | <0.001 * |
| Preop lymphocyte     | 4.10 ± 4.75            | 11.17 ± 7.90      | <0.001 * |
| Preop Hb (g/dL)      | 12.85 ± 2.13           | 9.70 ± 2.47       | <0.001 * |
| Preop Hct (%)        | 38.47 ± 6.13           | 29.47 ± 7.30      | <0.001 * |
| Preop PLT (/µL)      | 217,017.52 ± 71,052.99 | 168,704.08 ± 78,781.86 | <0.001 * |
| Preop MPV (fL)       | 9.26 ± 1.19            | 9.59 ± 1.24       | 0.023 * |
| Preop PLR            | 142.22 ± 84.14         | 155.52 ± 111.62   | 0.291   |
| Preop PT (INR)       | 1.06 ± 0.16            | 1.35 ± 0.42       | <0.001 * |
| Preop procalcitonin (ng/mL) | 0.18 ± 0.84     | 0.32 ± 0.39       | 0.245   |
| Preop CRP (mg/dL)    | 19.34 ± 35.91          | 30.08 ± 57.75     | 0.130   |
| Preop BNP (pg/mL)    | 201.50 ± 355.12        | 130.09 ± 189.65   | 0.149   |
| Preop lactate (mmol/L) | 0.97 ± 0.41            | 4.45 ± 2.66       | <0.001 * |

Values are presented as means ± standard deviations (%). NLR: neutrophil to lymphocyte ratio, Hb: hemoglobin, Hct: hematocrit, PLT: platelet, MPV: mean platelet volume, PLR: platelet to lymphocyte ratio, PT: prothrombin time, CRP: C-reactive protein, BNP: B type natriuretic peptide * p < 0.05.

4. Discussion

We investigated the relationship between the NLR, MPV, and PLR and 1-year mortality in patients who underwent an AAA open repair. High preoperative NLR was an independent risk factor for predicting 1-year mortality in patients with AAA along with ruptured cases. Both MPV and PLR were not significantly associated with mortality. According to a subgroup analysis based on the presence of ruptures, preoperative NLR and PLR were independent risk factors in ruptured cases, and no significant risk factors were found in non-rupture cases.

Neutrophilia and lymphopenia are physiologic responses of the innate immune system to various stressful insults, including systemic inflammation, injury, and stress [8]. Neutrophilia is reportedly observed during myocardial injury as a part of an acute inflammatory reaction [16]. Along with inflammation, neutrophilia is associated with platelet activation and atherothrombosis [17,18]. Lymphopenia is induced by hormones, cytokines, and chemokines and reflects the strength and intensity of a stressful event [8]. Moreover, it represents immune-depressed conditions in cases of increased lymphocyte apoptosis and has been utilized as an indicator of poor prognosis in patients with coronary heart disease [19]. Considering that both neutrophilia and lymphopenia increase the NLR, elevated NLR is correlated to poor prognosis. The previous literature has described a strong relationship between high NLR and poor outcomes in patients with acute coronary syndrome [16], coronary bypass graft [20], and acute aortic dissection [21]. Appleton et al. reported that preoperative NLR > 5 increased both 30-day mortality and long-term outcomes in open AAA surgery [6]. Moreover, NLR > 5 has been identified as an independent marker of 30-day morbidity in ruptured AAA [10]. In accordance with previous results, the preoperative NLR value was higher in the mortality group than in the survivor group. Moreover, the NLR had a prognostic impact on 1-year mortality in patients undergoing AAA open repair.

MPV is a biomarker of platelet activity and has been used as prognostic marker for adverse outcomes and mortality in various cohorts, such as coronary artery disease [12] and type A acute aortic dissection [22]. Considering that platelet activation plays a key role in atherothrombosis [23], MPV may exert a prognostic impact in patients with aortic disease.
Furthermore, MPV has been associated with aortic distensibility and chronic inflammation in patients with stable coronary artery disease [24]. However, the preoperative MPV was not significantly different between the survivors and non-survivors and failed to act as an independent predictor of 1-year mortality in patients undergoing AAA open repair. By contrast, we demonstrated that the MPV was significantly higher in ruptured cases than in non-ruptured cases. A possible explanation for this discrepancy is that platelets play an important role in ruptured cases. However, they are relatively unrelated to chronic inflammation, the primary pathogenesis of AAA. However, the possibility of a relatively small size being required to reach statistical significance or the existence of confounding factors necessitates further investigation.

The PLR is obtained by dividing the platelet count by the lymphocyte count, hence reflecting both thrombosis and inflammation [25]. Since PLR reflects inflammation, atherosclerosis, and platelet activation, previous researchers have reported on the prognostic impact of PLR in patients with various cardiovascular diseases [13,25]. The PLR levels at admission were associated with in-hospital mortality in patients with type A acute aortic dissection [21]. It is difficult to compare our findings with previous results since there are limited reports on the role of PLR in patients with AAA. A previous study demonstrated that extreme PLR values are associated with the risk of complications in patients undergoing AAA surgical repair [5]. Although PLR failed to predict 1-year mortality in all patients, PLR displayed a predictive power in patients with ruptured AAA in the current study. A possible explanation for the discrepancy was the occurrence of platelet consumption in the ruptured cases.

AAA is a progressive pathological dilatation of the aortic wall, characterized by chronic inflammation and atherothrombosis [9,26]. According to Kuivaniemie et al., theories of AAA pathogenesis include inflammation, smooth muscle cell apoptosis, extracellular matrix degradation and oxidative stress [27]. Furthermore, chronic inflammation also plays a central role in AAA progression [28,29]. Previous studies have reported that inflammatory cells, including T cells, macrophages, neutrophils, and mast cells infiltrate into the aortic walls, thus initiating and promoting AAA expansion [30]. Likewise, Dawson et al. reported that aortic aneurysm secret proinflammatory cytokine interleukin-6 and elevated circulating IL-6 were independent risk factors for cardiovascular mortality [31,32]. Therefore, higher NLR can supposedly predict poor prognosis in patients with AAAs. We suggested that MPV does not have prognostic value compared to NLR, considering that inflammation plays a key role in AAA development and progression.

However, CRP, which reflects systemic inflammation, was not significantly associated with mortality in patients with AAA. Previous studies on plasma cytokine levels in AAA reported a positive linear correlation between CRP levels and the aortic diameter [33,34]. Thus, elevated CRP in AAA disproves the involvement of inflammation in the development of AAA [35]. However, the association between CRP and AAA progression is unclear [36,37]. We observed no significant difference in CRP levels between the survivors and non-survivors, and between non-ruptured and ruptured AAA groups, in contrast to NLR results. CRP was primarily related to the development rather the expansion of AAA [37]. Thus, it may not have prognostic value as a predictor in patients with AAA. Additionally, this difference may be attributed not only to inflammation but also to platelet activation, atherothrombosis [17,18], and the intensity of stressful events, [8] considering that NLR involves both neutrophilia and lymphopenia.

The fact that NLR and PLR could predict prognosis in ruptured cases but not in non-ruptured cases means that inflammation and platelet consumption are more likely to occur in ruptured cases with mortality. This can be demonstrated by the significantly higher neutrophil and significantly lower lymphocyte and platelet counts in ruptured cases. In a recent study, shock, hemorrhage, and hypertensive disease were related as the cause of death in ruptured aneurysms, but only hypertensive disease was found to be related to unruptured aneurysms [4]. These results are consistent with our study in that NLR and PLR were predictive of 1-year mortality. Moreover, although it failed to obtain statistical
significance, the logistic regression analysis showed that hypertension had a tendency to predict death in non-ruptured cases, similar to the results of the previous study. Since the only validated measure of rupture risk is the diameter of an abdominal aortic aneurysm [3], an increased inflammatory marker in ruptured cases may be due to the involvement of inflammation in the expansion of an aneurysm rather than development of an aneurysm. Furthermore, these changes in NLR and PLR in ruptured cases with mortality may be partly due to the inflammation and platelet consumption caused by rupture.

The strengths of our study were that we predominantly investigated the prognostic value of NLR, MPV, and PLR in patients undergoing AAA open repair. Second, we included a relatively longer follow-up period, which has rarely been investigated before.

However, our study had some limitations. Considering the inherent nature of retrospective studies, we could collect existing data alone. Patients without available laboratory data were excluded, thus creating possibilities for selection bias. Second, although we investigated patients’ history of taking steroids and compared them between groups, it could be a limitation that we did not exclude patients taking steroids that could affect complete blood counts. Lastly, we selected all patients undergoing AAA open repair, including ruptured cases. However, patients with elective cases also have a substantial risk of rupture, and since NLR is related to the pathogenesis and progression of AAA rather than simply rupture, we think it is meaningful to analyze patients with abdominal aortic aneurysm across all spectrums including asymptomatic, symptomatic non-ruptured, and symptomatic ruptured cases. Furthermore, we additionally performed a subgroup analysis. Statistical significance may not have been reached in non-ruptured cases due to the small sample size, or due to the relatively low mortality. Furthermore, NLR and ruptured cases were identified as independent risk factors for mortality. This necessitates exploring the prognostic impact of NLR in both non-ruptured and ruptured cases.

5. Conclusions

In conclusion, NLR was identified as an independent predictor for 1-year mortality in patients undergoing AAA open repair. In a subgroup analysis, NLR and PLR were predictors of 1-year mortality in ruptured cases, but not in non-ruptured cases. However, MPV did not reveal a prognostic impact. NLR reflects chronic inflammation, which is the primary pathophysiology of developing AAA. Therefore, NLR rather than MPV could have a prognostic impact on patients with AAA.

Author Contributions: Data curation, H.J.Y.; formal analysis, D.E.K.; investigation, G.L.; supervision, S.B.N. and S.W.S.; validation, S.B.N. and S.Y.H.; visualization, H.J.Y.; writing—original draft, D.E.K. and S.Y.H.; writing—review and editing, S.Y.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Yonsei University Health System (protocol code 3-2020-0479 and date of approval: 11 January 2021).

Informed Consent Statement: Patient consent was waived due to the retrospective nature of this study.

Data Availability Statement: Due to internal institutional restrictions, raw data would remain confidential and would not be shared but would be made available on reasonable request and with the permission of the institution where the data were generated.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Sakalihasan, N.; Limet, R.; Defaye, O.D. Abdominal aortic aneurysm. *Lancet* 2005, 365, 1577–1589. [CrossRef]
2. Wieker, C.M.; Spazier, M.; Böckler, D. Indications for and outcome of open AAA repair in the endovascular era. *J. Cardiovasc. Surg.* 2016, 57, 185–190.
3. Nordon, I.M.; Hinchliffe, R.J.; Loftus, I.M.; Thompson, M.M. Pathophysiology and epidemiology of abdominal aortic aneu-rysms. *Nat. Rev. Cardiol.* 2011, 8, 92–102. [CrossRef]

4. Santo, A.H.; Puech-Leão, P.; Krutman, M. Trends in abdominal aortic aneurysm-related mortality in Brazil, 2000–2016: A multiple-cause-of-death study. *Clinics* 2021, 76, e2388. [CrossRef]

5. Lareyre, F.; Carboni, J.; Chikande, J.; Massiot, N.; Voury-Pons, A.; Umbdenstock, E.; Jean-Baptiste, E.; Hassen-Khodja, R.; Raffort, J. Association of Platelet to Lymphocyte Ratio and Risk of 30-Day Postoperative Complications in Patients Undergoing Abdominal Aortic Surgical Repair. *Vasc. Endovasc. Surg.* 2019, 53, 5–11. [CrossRef]

6. Appleton, N.D.; Bailey, D.M.; Morris-Stiff, G.; Lewis, M.H. Neutrophil to Lymphocyte Ratio Predicts Perioperative Mortality Following Open Elective Repair of Abdominal Aneurysms. *Vasc. Endovasc. Surg.* 2014, 48, 311–316. [CrossRef] [PubMed]

7. Aurelian, S.V.; Adrian, M.; Andercou, O.; Bruno, S.; Alexandru, O.; Catalin, T.; Dan, B. Neutrophil-to-Lymphocyte Ratio: A Comparative Study of Rupture of Nonruptured Infrarenal Abdominal Aortic Aneurysm. *Ann. Vasc. Surg.* 2019, 58, 270–275. [CrossRef] [PubMed]

8. Zahorec, R. Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill. *Bratislavské Lekarske Listy* 2001, 102, 5–14.

9. Golledge, J. Abdominal aortic aneurysm: Update on pathogenesis and medical treatments. *Nat. Rev. Cardiol.* 2019, 16, 225–242. [CrossRef] [PubMed]

10. Kordzadeh, A.; Malietzis, G.; Browne, T.; Prionidis, I.; Panayiotopoulos, Y.P. Neutrophil to lymphocyte ratio (NLR) of five predicts 30-day morbidity in ruptured abdominal aortic aneurysms (rAAA): A retrospective cohort study. *Int. J. Surg.* 2015, 15, 45–48. [CrossRef] [PubMed]

11. Bhutta, H.; Agha, R.; Wong, J.; Tang, T.Y.; Wilson, Y.G.; Walsh, S.R. Neutrophil-Lymphocyte Ratio Predicts Medium-Term Survival Following Elective Major Vascular Surgery: A Cross-Sectional Study. *Vasc. Endovasc. Surg.* 2011, 45, 227–231. [CrossRef] [PubMed]

12. Chu, S.G.; Becker, R.C.; Berger, P.B.; Bhatt, D.L.; Eikelboom, J.W.; Konkle, B.; Mohler, E.R.; Reilly, M.P.; Berger, J.S. Mean platelet volume as a predictor of cardiovascular risk: A systematic review and meta-analysis. *J. Thromb. Haemost.* 2010, 8, 148–156. [CrossRef] [PubMed]

13. Balta, S.; Ozturk, C. The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. *Platelets* 2015, 26, 680–681. [CrossRef] [PubMed]

14. Milovanovic Alempijevic, T.; Stojkovic Lalosevic, M.; Dumić, I.; Jocić, N.; Pavlović Marković, A.; Dragasević, S.; Jovic, I.; Lukić, S.; Popović, D.; Milosavljević, T. Diagnostic Accuracy of Platelet Count and Platelet Indices in Noninvasive Assess-ment of Fibrosis in Nonalcoholic Fatty Liver Disease Patients. *Can. J. Gastroenterol. Hepatol.* 2017, 2017, 6071035. [CrossRef]

15. Bath, J.; Smith, J.B.; Kruse, R.L.; Vogel, T.R. Association of neutrophil-to-lymphocyte ratio with outcomes after elective ab-dominal aortic aneurysm repair. *J. Vasc. Nurs.* 2019, 37, 213–220. [CrossRef] [PubMed]

16. Tamhane, U.U.; Aneja, S.; Montgomery, D.; Rogers, E.K.; Eagle, K.A.; Gurm, H.S. Association between admission neutro-phil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. *Am. J. Cardiol.* 2008, 102, 653–657. [CrossRef] [PubMed]

17. Siminiak, T.; Flores, N.A.; Sheridan, D.J. Neutrophil interactions with endothelium and platelets: Possible role in the develop-ment of cardiovascular injury. *Eur. Heart J.* 1995, 16, 160–170. [CrossRef]

18. Pircher, J.; Engelmann, B.; Massberg, S.; Schulz, C. Platelet–Neutrophil Crosstalk in Atherothrombosis. *Thromb. Haemost.* 2019, 119, 1274–1282. [CrossRef] [PubMed]

19. Lareyre, F.; Raffort, J.; Le, D.; Chan, H.L.; Le Houerou, T.; Cochennec, F.; Touma, J.; Desgranges, P. High Neutrophil to Lymphocyte Ratio Is Associated with Symptomatic and Ruptured Thoracic Aortic Aneurysm. *Angiology* 2018, 69, 686–691. [CrossRef] [PubMed]

20. Gibson, P.H.; Croal, B.L.; Cuthbertson, B.H.; Small, G.R.; Ifezulike, A.I.; Gibson, G.; Jeffrey, R.R.; Buchan, K.G.; El-Shafei, H.; Hillis, G.S. Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting. *Am. Heart J.* 2007, 154, 995–1002. [CrossRef] [PubMed]

21. Bedel, C.; Selvi, F. Association of Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios with In-Hospital Mortality in Patients with Type A Acute Aortic Dissection. *Braz. J. Cardiovasc. Surg.* 2019, 34, 694–698. [CrossRef] [PubMed]

22. Li, D.-Z.; Chen, Q.-J.; Sun, H.-P.; Zeng, R.; Zeng, Z.; Gao, X.-M.; Ma, Y.-T.; Yang, Y.-N. Mean platelet volume to platelet count ratio predicts short-term mortality in type A acute aortic dissection. *Blood Coagul. Fibrinolysis* 2016, 27, 653–659. [CrossRef] [PubMed]

23. Dav, E.; Patrano, C. Platelet Activation and Atherothrombosis. *N. Engl. J. Med.* 2007, 357, 2482–2494. [CrossRef]

24. ahin, D.Y.; Gür, M.; Elbasan, Z.; Yildrim, A.; Akilli, R.E.; Koyunsever, N.Y.; Özaltun, B.; Gözübüyük, G.; Kivrak, A.; Çaylı, M. Mean platelet volume associated with aortic stenosis, chronic inflammation, and diabetes in patients with stable coronary artery disease. *Clin. Appl. Thromb. Hemost.* 2014, 20, 416–421. [CrossRef]

25. Kurtul, A.; Ornek, E. Platelet to Lymphocyte Ratio in Cardiovascular Diseases: A Systematic Review. *Angiology* 2019, 70, 802–818. [CrossRef]

26. Erhart, P.; Cakmak, S.; Grond-Ginsbach, C.; Hakimi, M.; Böckler, D.; Dihlmann, S. Inflammation activity in leukocytes decreases with abdominal aortic aneurysm progression. *Int. J. Mol. Med.* 2019, 44, 1299–1308. [CrossRef] [PubMed]

27. Kuivaniemi, H.; Ryer, E.J.; Elmore, J.R.; Tromp, G. Understanding the pathogenesis of abdominal aortic aneurysms. *Expert. Rev. Cardiovasc. Ther.* 2015, 13, 975–987. [CrossRef] [PubMed]
28. Dale, M.A.; Ruhlman, M.K.; Baxter, B.T. Inflammatory cell phenotypes in aaas: Their role and potential as targets for therapy. *Arterioscler. Thromb. Vasc. Biol.* **2015**, *35*, 1746–1755. [CrossRef]

29. Li, H.; Bai, S.; Ao, Q.; Wang, X.; Tian, X.; Li, X.; Tong, H.; Hou, W.; Fan, J. Modulation of Immune-Inflammatory Responses in Abdominal Aortic Aneurysm: Emerging Molecular Targets. *J. Immunol. Res.* **2018**, *2018*, 1–15. [CrossRef]

30. Yuan, Z.; Lu, Y.; Wei, J.; Wu, J.; Yang, J.; Cai, Z. Abdominal Aortic Aneurysm: Roles of Inflammatory Cells. *Front. Immunol.* **2020**, *11*, 3758. [CrossRef]

31. Dawson, J.; Cockerill, G.; Choke, E.; Loftus, I.; Thompson, M.M. Aortic Aneurysms as a Source of Circulating Interleukin-6. *Ann. N. Y. Acad. Sci.* **2006**, *1085*, 320–323. [CrossRef]

32. Dawson, J.; Cockerill, G.W.; Choke, E.; Belli, A.-M.; Loftus, I.; Thompson, M.M. Aortic aneurysms secrete interleukin-6 into the circulation. *J. Vasc. Surg.* **2007**, *45*, 350–356. [CrossRef]

33. Liao, M.; Liu, C.-L.; Lv, B.-J.; Zhang, J.-Y.; Cheng, L.; Cheng, X.; Lindholt, J.S.; Rasmussen, L.M.; Shi, G.-P. Plasma cytokine levels and risks of abdominal aortic aneurysms: A population-based prospective cohort study. *Ann. Med.* **2015**, *47*, 245–252. [CrossRef] [PubMed]

34. Vega de Céniga, M.; Esteban, M.; Quintana, J.M.; Barba, A.; Estallo, L.; de la Fuente, N.; Viviens, B.; Martin-Ventura, J.L. Search for Serum Biomarkers Associated with Abdominal Aortic Aneurysm Growth—A Pilot Study. *Eur. J. Vasc. Endovasc. Surg.* **2009**, *37*, 297–299. [CrossRef] [PubMed]

35. Vainas, T.; Lubbers, T.; Stassen, F.R.; Herngreen, S.B.; van Dieijen-Visser, M.P.; Bruggeman, C.A.; Kitslaar, P.J.; Schurink, G.W. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. *Circulation* **2003**, *107*, 1103–1105. [CrossRef] [PubMed]

36. Juvonen, J.; Surcel, H.M.; Satta, J.; Teppo, A.M.; Bloigu, A.; Syrjälä, H.; Airaksinen, J.; Leinonen, M.; Saikku, P.; Juvonen, T. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. *Arterioscler. Thromb. Vasc. Biol.* **1997**, *17*, 2843–2847. [CrossRef] [PubMed]

37. Hellenthal, F.A.; Buurman, W.A.; Wodzig, W.K.; Schurink, G.W. Biomarkers of abdominal aortic aneurysm progression. Part 2: Inflammation. *Nat. Rev. Cardiol.* **2009**, *6*, 543–552. [CrossRef]